Project Grant R01AI181854

Award Date 5/10/24
Completion Date 3/31/29
Dollars Obligated $2.2M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to examine the role of B cell-dependent regulatory T cells in maintaining B cell tolerance and preventing autoimmunity. The $807,799 award to the University of Chicago aims to identify B cell-dependent regulatory T cell clones, define their developmental requirements and functions, and determine the...
This Project Grant award of $1,083,816.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of Colorado-Denver to investigate the role of CD79A as a molecular switch regulating B cell activation and tolerance. The key objectives are to determine how individual CD79A immunoreceptor tyrosine-based activation motif (ITAM) tyrosines impact B cell receptor (BCR) signaling and downstream...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $766,265 to the University of Chicago to conduct research on the role of regulatory T cells (Tregs) in establishing and maintaining transplantation tolerance. The research aims to elucidate the mechanisms by which Tregs program alloreactive T cell anergy during the induction phase of tolerance, as well as the mechanisms by which the elimination...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,288,215 to The University of Texas MD Anderson Cancer Center to conduct research on the role of the GRAIL gene in B cell tolerance and B cell-mediated inflammation. The key objectives are to: Determine the molecular mechanisms by which GRAIL regulates B cell tolerance and activation. This will involve identifying the specific targets and...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to determine how germinal center (GC) responses are controlled in health and how governance loss promotes immune deficiencies and autoimmune diseases. The key objectives are to establish the lineage and functional differences between induced T follicular regulatory (iTFR) and natural TFR (nTFR) cells, and assess...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA Program 93.855 Allergy and Infectious Diseases Research, is funding a $556,843 research initiative at the University of Pittsburgh to investigate the development and regulation of the extrafollicular B cell response. The key objectives are to: Examine the role of B cells in enhancing the extrafollicular response and test the self-renewal capacity of the extrafollicular B cell population....
This Project Grant award of $194,740 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to characterize the development of lung-resident, self-antigen-specific regulatory T cells (Tregs) following acute lung injury. The goal is to understand how these "experienced" Tregs can promote tolerance and prevent future autoimmunity. The principal investigator, Dr. Daniel Shin at...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $379,609 to the University of Pittsburgh to investigate B cell tolerance to commensal antigens. The research aims to: 1) Define contexts in which B cell tolerance to commensal antigens is perturbed, 2) Isolate specific commensal bacteria that interact with LPS-specific B cell receptors to further understand tolerance...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $202,488.00 to Cedars-Sinai Medical Center to conduct research on the functional roles of TOX isoforms in T cell and innate lymphoid cell (ILC) development. The key objectives of this 2-year project are to: 1) Perform a comprehensive analysis of T cell and ILC development in a novel mouse model (D37) that lacks the TOX long (TOXL)...
This Project Grant award, totaling $441,098.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The grant aims to investigate the antagonistic relationship between the transcription factors IRF4 and BACH2 in regulating germinal center B cell fates and promoting lymphomagenesis. The research project, with a performance period from July 2025 to June 2027, will use transgenic...

CONTRIBUTION AND INTERPLAY OF CXCR4 AND INTEGRINS IN CENTRAL B CELL TOLERANCE - PROJECT SUMMARY THE OBJECTIVE OF THIS RESEARCH IS TO UNDERSTAND THE ROLE AND MECHANISM BY WHICH CHEMOATTRACTANT AND INTEGRIN SIGNALING PLAYS IN THE BONE MARROW SELECTION OF B CELLS AND IN SHAPING THE PERIPHERAL PRIMARY B CELL REPERTOIRE AND ITS DEGREE OF SELF-REACTIVITY. THE FACT THAT 30% OF THE MILLIONS OF B CELLS PRODUCED DAILY EXPRESS A B CELL RECEPTOR WITH HIGH-AVIDITY FOR SELF-ANTIGEN SUGGESTS WE MAY NOT BE HEALTHY AND LIVE A FULL LIFE IN THE ABSENCE OF CENTRAL B CELL TOLERANCE. INTRIGUINGLY, INDIVIDUALS AFFECTED BY COMMON AUTOIMMUNE DISEASES DISPLAY DEFECTS OF CENTRAL B CELL TOLERANCE MANIFESTING WITH MUCH HIGHER NUMBERS OF BONE MARROW AUTOREACTIVE B CELLS ENTERING THE PERIPHERAL TISSUE. HOWEVER, THESE INDIVIDUALS ALSO HAVE DEFECTS IN PERIPHERAL TOLERANCE. A BETTER UNDERSTANDING OF HOW NEWLY GENERATED HIGH-AVIDITY AUTOREACTIVE B CELLS ARE CONTROLLED BY OR ESCAPE TOLERANCE CAN HAVE PROFOUND IMPLICATIONS FOR THE DEVELOPMENT OF THERAPIES THAT MAY REDUCE THE SELF-REACTIVE BURDEN OF THE CIRCULATING B CELL POPULATION IN INDIVIDUALS PREDISPOSED TO AUTOIMMUNITY. WE HAVE RECENTLY DOCUMENTED THAT THE CHEMOKINE RECEPTOR CXCR4 IS EXPRESSED AT HIGHER LEVELS BY AUTOREACTIVE B CELLS UNDERGOING CENTRAL TOLERANCE THAN NON-SELF-REACTIVE B CELLS LICENSED TO LEAVE THE BONE MARROW. MOREOVER, IN VIVO TREATMENT OF MICE WITH A CXCR4 ANTAGONIST, RELEASES HIGH-AVIDITY AUTOREACTIVE B CELLS FROM THE BONE MARROW INTO THE CIRCULATION FROM WHERE THEY RELOCATE INTO THE SPLEEN. THE MECHANISMS BY WHICH CXCR4 SIGNALING RETAINS SELF-REACTIVE B CELLS WITHIN THE BONE MARROW IS NOT CLEAR. IT IS KNOWN THAT CXCR4 SIGNALING CAN MODULATE THE FUNCTION OF INTEGRINS, MOLECULES THAT REGULATE CELL ADHESION TO TISSUES. CHEMOKINE RECEPTORS AND INTEGRINS CAN ALSO BE REGULATED BY PI3K SIGNALING OR CAN THEMSELVES PROMOTE THE ACTIVITY OF PI3K, WHICH IS IMPORTANT FOR THE POSITIVE SELECTION OF IMMATURE B CELLS OUT OF THE BONE MARROW. THE GOAL OF THIS GRANT IS TO DEFINE THE CONTRIBUTION OF CXCR4 AND INTEGRIN RECEPTORS TO CENTRAL B CELL TOLERANCE AND THE IMPACT OF CENTRAL B CELL TOLERANCE ON PERIPHERAL TOLERANCE AND AUTOIMMUNE RESPONSES. EXPERIMENTS IN AIM 1 WILL ESTABLISH WHETHER CXCR4 SIGNALING CONTROLS THE BONE MARROW RETENTION OF AUTOREACTIVE B CELLS IN HUMAN BEINGS. AIM 2 WILL RESOLVE THE CONTRIBUTION OF INTEGRINS IN BONE MARROW B CELL SELECTION AND THE CROSSTALK BETWEEN CXCR4, INTEGRINS AND PI3K. EXPERIMENTS IN AIM 3 WILL TEST THE HYPOTHESIS THAT THE CXCR4-MEDIATED CENTRAL B CELL TOLERANCE PROCESS IS NECESSARY TO REDUCE THE CHANCES OF SYSTEMIC AUTOANTIBODY AND AUTOIMMUNE RESPONSES. OVERALL, THESE STUDIES ARE SIGNIFICANT BECAUSE THEY GENERATE A DEEPER MECHANISTIC UNDERSTANDING OF HOW B CELL TOLERANCE CAN BE BREACHED DURING THE DEVELOPMENT OF AUTOREACTIVE B CELLS TO RAISE THE AUTOREACTIVE CAPACITY OF THE PRIMARY CIRCULATING B CELL REPERTOIRE AND THE GENERAL RISK FOR AUTOIMMUNITY.

Posted 5/10/24, 12:00 AM